[December 13, 2016]

Vyome Presents on the Development of the Dual Action Rational Therapeutics Platform at the 2016 ASM Conference on Antibacterial Development

Vyome Biosciences, a clinical-stage specialty biopharmaceutical company developing novel medicines for treating diseases caused by drug-resistance in the skin microbiome, will present two posters at the American Society of Microbiology's ASM (News - Alert) Conference on Antibacterial Development 2016. The posters highlight the company's novel Dual Action Rational Therapeutics (DARTs) technology, and its potential to develop effective drug candidates that minimize the risk of developing antibiotic resistance.

The company will present "Development of a Novel Antibiotic VCD-008 for the Treatment of Medical Device Associated Orthopedic Infections" at the Antibiotics poster session on Dec. 13. Vyome's patented DARTs technology has the potential to improve treatment of antibiotic-resistant infections from skin opportunist pathogens, such as implant infection, which have increased in recent years due to the growing geriatric population. Vyome is developing VCD-008, a new generation antibiotic, that is being evaluated to improve efficacy for the treatment of device-related osteomyelitis. In silico screenings showed that VCD-008 has excellent activity against S. epidermidis and Propionibacterium acnes (P. acnes), and has demonstrated a low propensity to develop resistance than current treatments, such as clindamycin and fluoroquinolones.

The company wil also discuss the DARTs technology platform in the presentation, "Development of a Library of Novel Fluoroquinolones with Coveted Antibiotic Properties" during the ASM conference. Resistance against Gram-positive and Gram-negative bacteria, especially fluoroquinolones, has increased in recent years, despite limited use based on prescribing guidelines, especially with life threatening and skin opportunist bacteria like Staphylococcus aureus & Staphylococcus epidermidis. "Vyome is utilizing a rational structure-based drug design to develop new antibiotics that have multi-mode activities to bypass and/or suppress this resistance and develop novel treatment options. Vyome's screening process is to develop and leverage molecules with potent bactericidal activity against resistant strains, while maintaining low propensity in emergence of resistance; for example, VCD-011 imparts effective bio-film inhibitory properties against Staphylococcus," explained Dr. Shiladitya Sengupta, Co-Founder of Vyome Biosciences and Assistant Professor of Medicine at Harvard Medical School.

"Vyome is developing the DARTs platform to combat the worldwide issue of antibiotic resistance in the skin microbiome. Our current data has demonstrated efficacy as certain DART molecules are effective in decreasing the propensity for resistance in multiple bacterial strains, such as VCD-008 in P. acnes," said Venkateswarlu Nelabhotla (N. Venkat), Co-Founder and Chief Executive Officer of Vyome Biosciences.

About Vyome Biosciences

Vyome Biosciences is an innovation-driven, clinical stage specialty bio-pharmaceutical company, which has novel platform technologies and a deep pipeline that addresses drug-resistant skin opportunistic pathogens such as antibiotic resistant acne. Vyome's lead program VB 1953, which targets the unmet need of antibiotic resistant acne, is currently under evaluation in U.S. FDA Phase 1 clinical studies. Vyome also has a deep pipeline of preclinical new chemical entities, unique in their ability to overcome the development of resistance based on patented Dual Action Rational Therapeutics (DARTs) technology. In addition, Vyome has developed clinically proven antifungal products based on an innovative technology platform, Molecular Replacement Therapy (MRT™). Vyome has assembled a world-class team of scientific experts from India and the United States who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at http://www.vyome.in.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161213005878/en/

[ Back To TMCnet.com's Homepage ]